Emet Surgical

Executive Summary

Emet Surgical is pioneering AI-driven precision in minimally invasive surgery with its ESP (Enhanced Surgical Precision) platform. The software integrates with existing laparoscopic and robotic systems to provide real-time visual overlay guidance, detecting anomalies that may escape the human eye. This aims to reduce intraoperative errors and improve patient outcomes, addressing a critical need in the $40B+ global surgical device market. Founded in 2019 and based in San Francisco, the company is positioning itself as a key enabler in the shift toward data-driven surgery. Despite its early stage, Emet has a clear regulatory pathway ahead. The platform is classified as a Software-as-a-Medical-Device (SaMD) and will require FDA 510(k) clearance. The company is expected to submit its premarket notification within the next 12 months. While no funding rounds or partnerships have been disclosed, the team's focus on interoperability with existing equipment reduces adoption barriers. Success will depend on clinical validation and securing partnerships with leading robotic surgery platforms. With AI in surgery gaining rapid adoption, Emet Surgical could carve out a niche in real-time intraoperative decision support.

Upcoming Catalysts (preview)

• H2 2026FDA 510(k) Submission for ESP Platform60% success
• Q4 2026Publication of Clinical Validation Study70% success
• Q3 2026Strategic Partnership with Robotic Surgery OEM50% success